Dr. Beth A Avolio, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 21955 Stanford Cir, Elkhorn, NE 68022 Phone: 402-763-9422 |
Briana Marie Momchilovich, MA, PLMHP Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1011 N 192nd Ct Apt 226, Elkhorn, NE 68022 Phone: 651-324-6546 |
News Archive
Illinois Gov. Rod Blagojevich (D) on Sunday unveiled a plan to expand access to health insurance to the 1.4 million uninsured state residents at an estimated cost of $2.1 billion per year, the Chicago Tribune reports.
X-rays are not the only way: visible and especially infrared light can also be used to image human tissue. The effectiveness of optical imaging processes can be significantly improved with suitable dyes used as contrast agents. In the journal Angewandte Chemie, a team led by Wenbin Lin at the University of North Carolina (Chapel Hill, USA) has now introduced a novel contrast agent that marks tumor cells in vitro. The dye is a phosphorescent ruthenium complex incorporated into nanoparticles of a metal–organic coordination polymer, which allows an extraordinarily high level of dye loading.
The researchers, Professor Michael Eysenck and Dr Nazanin Derkshan, designed several experiments to explore the effects of anxiety on our ability to perform tasks such as avoiding distractions on a computer screen, when reading a story, or solving a series of simple mathematics problems.
Today the United States Centers for Disease Control and Prevention issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis. In these landmark guidelines, CDC advises that Interferon Gamma Release Assay blood tests are now preferred over the 100+-year-old tuberculin skin test for diagnosing TB infection in certain populations, including people who typically do not return for the necessary reading of TST results, and those who have received Bacille Calmette-Guerin as a vaccine or for cancer therapy
Bio-Matrix Scientific Group, Inc. and Its majority owned subsidiary Entest BioMedical Inc. announced today they have finalized a definitive agreement with Therinject LLC for the development of a new immuno-therapeutic cancer vaccine. Therinject LLC is engaged in the development of cancer treatments utilizing immunology based approaches.
› Verified 2 days ago